You just read:

Takeda Canada announces positive results for ENTYVIO® (vedolizumab) vs. Humira® (adalimumab) in first IBD study to compare biological agents head-to-head

News provided by

Takeda Canada Inc.

Mar 11, 2019, 07:00 ET